Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05151016
Other study ID # 20210229
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date December 1, 2021
Est. completion date December 31, 2023

Study information

Verified date November 2021
Source Women's Hospital School Of Medicine Zhejiang University
Contact Xinmei Zhang, M.D.
Phone (+86)18957110072
Email zxm20130729@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The design was a prospective, randomized, positive-control, parallel-group, multicenter clinical trial. The study included a randomized, parallel-group treatment for 24 weeks in 140 subjects from eight hospitals in seven cities across the country who were diagnosed with Adenomyosis and associated symptoms (dysmenorrhea, with or without heavy menstrual flow) , the subjects were randomly assigned to the following two groups: 1. Study Group: mifepristone tablets, 10 mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks; 2. Control Group: dafinil (Triptorelin Acetate) , 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 140
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion criteria. - Female, over 18 years old and not menopausal, agree to tripriline acetate and mifepristone treatment and informed consent - Patients were diagnosed as adenomyosis by postoperative pathology, or those who did not undergo surgery but were diagnosed by auxiliary examination, such as ultrasonography and MRI. - Dysmenorrhea with or Without Menorrhagia - Requiring preservation of the uterus or fertility - No other hormonal treatment for Adenomyosis was received in the three months prior to treatment - Normal or non-clinically significant cervical cytology results (6 months before the screening period) Exclusion criteria. - Pelvic pain and vaginal bleeding of unknown or non-Adenomyosis causes - Benign Lesions such as endometrial polyp, submucous Myoma or suspicious malignant tumors were diagnosed by ultrasonography - Receiving other hormone drugs for Adenomyosis - Use other drugs that interact with tripriline acetate and mifepristone, and can not be stopped - Patients with severe heart, liver, kidney disease and Adrenal insufficiency; drug allergy or allergic constitution - Participated in other clinical trials within 3 months, and other factors considered unsuitable for the trial - Pregnant, lactating women and those who prepare for childbirth during the treatment or within six months after treatment - Postmenopausal women.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
mifepristone
Mifepristone tablets, 10mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks
Triptorelin Acetate
dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.

Locations

Country Name City State
China Women's Hospital of Zhejiang Medical University Hangzhou Zhejiang

Sponsors (8)

Lead Sponsor Collaborator
Women's Hospital School Of Medicine Zhejiang University Anhui Provincial Hospital, Jiaxing Maternity and Child Health Care Hospital, Ningbo Women & Children's Hospital, Obstetrics & Gynecology Hospital of Fudan University, Qilu Hospital of Shandong University, The Affiliated Hospital of Medical School, Ningbo University, The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in Pain on the Visual Analogue Scale (VAS) at week 24 The VAS is the most commonly used instrument assessing pain in clinical practice. It reflects the patient's subjective perception of pain. Possible scores range from 0 (no pain) to 10 (worst possible pain). The last observation carry forward was used for missing data.
Change=(Week 24 Score - Baseline Score)
Baseline and Week 24
Secondary Pictorial blood loss assessment chart(PBAC) Recording the use of tampons and sanitary towels by placing a tally mark under the day next to the box. Record clots by indicating whether they are the size of a 1p or 50pcoin in the clots/ flooding row under the relevant day. E.g. under day1 you may say 50p*1 and 1p*3. Record any incidences of flooding by placing a tally mark in the clots/ flooding row under the relevant day. A lightly stained towel (pic 1) will score 1 point, a moderately stained towel (pic 2) 5 points, a towel which is saturated with blood(pic 3) will score 20 points. A lightly stained tampon (pic 4) will score 1 point, a moderately stained tampon (pic 5) 5 points and a tampon that is fully saturated will score 10 points. A clot the size of 1p scores 1 point, a 50p sized clot scores 5 pointsand flooding also scores 5 points. Finally, total up the scores. A score of100 or greater may indicate a heavy period.
Change=Week 24 Score - Baseline Score
Baseline and week 24
Secondary Change from baseline in uterine size at week 24 Uterine size usually reflects the size of the adenomyosis lesion, and is measured in cubic centimeters.
Change=(Week 24 Uterine Size - Baseline Uterine Size)*0.5236
Baseline and week 24
Secondary Change from baseline in hemoglobin at week 24 Hemoglobin, measured in grams per liter, reflects a patient's level of menstrual blood loss.
Change=(Week 24 Hemoglobin Content - Baseline Hemoglobin Content)
Baseline and week 24
Secondary Change from baseline in CA125 at week 24 CA125 is measured in micrograms per liter. Change=(Week 24 Hemoglobin Content - Baseline Hemoglobin Content) Baseline and week 24
See also
  Status Clinical Trial Phase
Completed NCT04665414 - Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI
Recruiting NCT04209127 - Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis N/A
Completed NCT05751876 - Dienogest in Perimenopausal Women With Adenomyosis
Recruiting NCT01048931 - Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Phase 3
Active, not recruiting NCT06223464 - Evaluation of the Relationship Between Adenomyosis and Elastographic Properties of the Cervix
Completed NCT05419414 - The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis N/A
Recruiting NCT05152667 - Ambispective Study to Assess the Effect of Pretreatment With a Levonorgestrel-Releasing Intrauterine System Versus Oral Progestin
Not yet recruiting NCT03654144 - Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Phase 4
Completed NCT02192606 - Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? N/A
Completed NCT01992718 - What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Early Phase 1
Recruiting NCT02495311 - The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms
Recruiting NCT03742843 - A Multi-omics Study of Adenomyosis
Recruiting NCT04481321 - Clinical and Molecular Study of Endometriosis and Adenomyosis
Recruiting NCT04894292 - The Effect of Adenomoyosis on Pregnancy Outcomes
Completed NCT03520439 - Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Phase 2/Phase 3
Recruiting NCT05937490 - Adenomyosis and ART Phase 4
Recruiting NCT06373822 - New Perspectives in Adenomyosis Pathogenesis With Epigenetic Analysis and miRNAs
Completed NCT01821001 - Vaginal Bromocriptine for Treatment of Adenomyosis Phase 1
Recruiting NCT04295109 - Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function N/A
Recruiting NCT04356664 - Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Phase 2/Phase 3